| 2024 | Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with BRCA mutation and/or maintenance therapy | JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2024 | Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial | LANCET |
| 2024 | Pembrolizumab or Placebo With Chemoradiotherapy Followed by Pembrolizumab or Placebo for Newly Diagnosed, High-Risk, Locally Advanced Cervical Cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): A Randomized, Double-Blind, Phase 3 Clinical Trial | OBSTETRICAL & GYNECOLOGICAL SURVEY |
| 2024 | Anti-4-1BB×PDL1 Bispecific Antibody Reinvigorates Tumor-Specific Exhausted CD8+ T Cells and Enhances the Efficacy of Anti-PD1 Blockade | CLINICAL CANCER RESEARCH |
| 2024 | Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis | GYNECOLOGIC ONCOLOGY |
| 2024 | Unique immune characteristics and differential anti-PD-1-mediated reinvigoration potential of CD8 + TILs based on BRCA1/2 mutation status in epithelial ovarian cancers
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2024 | Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2024 | Histopathologic image-based deep learning classifier for predicting platinum-based treatment responses in high-grade serous ovarian cancer
| NATURE COMMUNICATIONS |
| 2024 | Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial | LANCET |
| 2024 | RAD51 as an immunohistochemistry-based marker of poly(ADP-ribose) polymerase inhibitor resistance in ovarian cancer
| FRONTIERS IN ONCOLOGY |
| 2024 | Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer
| SCIENTIFIC REPORTS |
| 2024 | The effectiveness of CA125 and HE4 as clinical prognostic markers in epithelial ovarian cancer patients with BRCA mutation
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2024 | Durvalumab with or without tremelimumab plus chemotherapy in HRR non-mutated, platinum-resistant ovarian cancer (KGOG 3045): A phase II umbrella trial | GYNECOLOGIC ONCOLOGY |
| 2024 | Application of Small Cell Lung Cancer Molecular Subtyping Markers to Small Cell Neuroendocrine Carcinoma of the Cervix: NEUROD1 as a Poor Prognostic Factor | AMERICAN JOURNAL OF SURGICAL PATHOLOGY |
| 2024 | Efficacy and safety of BVAC-C in HPV type 16- or 18-positive cervical carcinoma who failed 1st platinum-based chemotherapy: a phase I/IIa study
| FRONTIERS IN IMMUNOLOGY |
| 2024 | Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2024 | Reply to: Comments on "Randomized, two-arm, non-comparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045 | INTERNATIONAL JOURNAL OF CANCER |
| 2024 | Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125 | GYNECOLOGIC ONCOLOGY |
| 2024 | Serial Circulating Tumor DNA Analysis with a Tumor-Naïve Next-Generation Sequencing Panel Detects Minimal Residual Disease and Predicts Outcome in Ovarian Cancer | CANCER RESEARCH |
| 2024 | Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2024 | Clinical guidelines for ovarian cancer: the Korean Society of Gynecologic Oncology guidelines
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2024 | Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
| JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Initial experience with the da Vinci SP robot-assisted surgical staging of endometrial cancer: a retrospective comparison with conventional laparotomy | JOURNAL OF ROBOTIC SURGERY |
| 2023 | Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer | NEW ENGLAND JOURNAL OF MEDICINE |
| 2023 | Genomic hypomethylation in cell-free DNA predicts responses to checkpoint blockade in lung and breast cancer
| SCIENTIFIC REPORTS |
| 2023 | Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial | LANCET ONCOLOGY |
| 2023 | Secondary cytoreductive surgery with and without hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer
| GLAND SURGERY |
| 2023 | Randomized, two-arm, noncomparative phase 2 study of olaparib plus cediranib or durvalumab in HRR-mutated, platinum-resistant ovarian cancer: A substudy of KGOG 3045 | INTERNATIONAL JOURNAL OF CANCER |
| 2023 | Globally shared TCR repertoires within the tumor-infiltrating lymphocytes of patients with metastatic gynecologic cancer
| SCIENTIFIC REPORTS |
| 2023 | Incidence and survival of gynecologic cancer including cervical, uterine, ovarian, vaginal, vulvar cancer and gestational trophoblastic neoplasia in Korea, 1999-2019: Korea Central Cancer Registry
| Obstetrics & Gynecology Science |
| 2023 | Impact of PARP inhibitor maintenance therapy in newly diagnosed advanced epithelial ovarian cancer: A meta-analysis
| PLOS ONE |
| 2023 | Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy | JAMA SURGERY |
| 2023 | Comparison of Single-Port Laparoscopy with Other Surgical Approaches in Endometrial Cancer Surgical Staging: Propensity-Score-Matched Analysis
| CANCERS |
| 2023 | Frequency of peripheral PD-1+regulatory T cells is associated with treatment responses to PARP inhibitor maintenance in patients with epithelial ovarian cancer | BRITISH JOURNAL OF CANCER |
| 2023 | Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D
| JOURNAL FOR IMMUNOTHERAPY OF CANCER |
| 2023 | Study protocol for prospective multi-institutional phase III trial of standard of care therapy with or without stereotactic ablative radiation therapy for recurrent ovarian cancer (SABR-ROC)
| BMC CANCER |
| 2023 | Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
| NATURE COMMUNICATIONS |
| 2023 | Comparison of oncological outcomes between sentinel lymph node biopsy and complete lymphadenectomy for endometrial cancer | JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH |
| 2023 | Investigation of PARP Inhibitor Resistance Based on Serially Collected Circulating Tumor DNA in Patients With BRCA-Mutated Ovarian Cancer | CLINICAL CANCER RESEARCH |
| 2023 | Comparing surgical outcomes of da Vinci SP and da Vinci Xi for endometrial cancer surgical staging in a propensity score-matched study
| SCIENTIFIC REPORTS |
| 2023 | RAD51/geminin/γH2AX immunohistochemical expression predicts platinum-based chemotherapy response in ovarian high-grade serous carcinoma
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression. | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results. | JOURNAL OF CLINICAL ONCOLOGY |
| 2023 | Application of precision medicine based on next-generation sequencing and immunohistochemistry in ovarian cancer: a real-world experience
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Sentinel lymph node biopsy in endometrial cancer: The new norm - A multicentre, international experience | SURGICAL ONCOLOGY-OXFORD |
| 2023 | CEACAM1 Marks Highly Suppressive Intratumoral Regulatory T Cells for Targeted Depletion Therapy | CLINICAL CANCER RESEARCH |
| 2023 | Comprehensive genomic and immunohistochemical profiles and outcomes of immunotherapy in patients with recurrent or advanced cervical cancer
| FRONTIERS IN ONCOLOGY |
| 2023 | BNT162b2 접종과 면역관문억제제 치료 이후 발생한 이상 반응 1예
| Korean Journal of Medicine |
| 2023 | Role of diagnostic laparoscopy in deciding primary treatment in advanced-stage ovarian cancer
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
| 2023 | Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3
| JOURNAL OF GYNECOLOGIC ONCOLOGY |
http://orcid.org/0000-0001-7948-1350
(56191369600)
